FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Trial details
- Registry ID
- NCT07446322
- Phase
- Phase 2
Drug identity checked against registry records
| No regulatory events match this view.This does not mean no FDA events have occurred. |